Otsuka’s SIMTRIYO has FDA approval, but two hurdles will decide whether it can disrupt ADHD care
Otsuka’s SIMTRIYO wins FDA approval for ADHD, but DEA scheduling, boxed warnings and payer access will shape its commercial uptake.
Pharma & Biotech